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Abstract:
This study was planned to
compare recurrence of goiters after
thyroidectomy in patients who received
prophylactic levothyroxine and patients who
received no therapy. One hundred and
twenty-six patients had been treated by
bilateral subtotal thyroidectomy in the
General Surgery Clinic of Karadeniz Technical
University from 1987 to 1992. Eithy-eight
of these patients were included in this study
while the remaining patients were excluded
as they were non contactable. They were
divided into two groups. In group 1, there
were 41 patients who had received
prophylactic therapy with thyroxine 100
micro grams daily for a period of 9 to 12
months. Group 2 was composed of 47
patients without thyroxine therapy except 11
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Introduction
At present, nodular goiter is the most common
endocrine problem worldwide (1). In general it affects
3% to 4% of the population (2) but becomes a special
health problem in endemic goiter areas, appearing in
more than 10% of the population (1-3). Our hospital
serves an endemic goiter area of Turkey (4).
There is still considerable controversy about the
cause, optimum surgical treatment and efficacy of using
exogenous thyroxine medication postoperatively in
preventing recurrent goiter (5). Some recent publications
have described the autonomous nature of multinodular
goiter and have reported that postoperative thyroxine
does not have a beneficial effect in preventing recurrent
goiter (6-16). Other studies reported that not only
suppressive therapy of thyroid stimulating hormone
(TSH) decreases the incidence of goiter recurrences but
also prophylactic thyroxine therapy for long or short
periods postoperatively (3, 5, 17-25). There is no general
agreement among the authors about the effectiveness of
thyroxine use postoperatively in preventing recurrences.

cases who had received thyroxine for 20 days
or less irregularly. The mean follow-up
period for all cases was 6.5 years with a
range of 4 to 8 years. The results were
compared using Fisher’s exact test. The
recurrence rates were 7.3% (3 cases) and
25.5% (12 cases) in group 1 and group 2
respectively. The difference in recurrence was
found to be statistically significant (p<0.05).
Although the follow-up period was limited,
we
think
routine
postotoperative
prophylactic thyroxine therapy for 9 to 12
months in patients who have had an
operation for benign nodular goiter has
clinical value.
Key Words: Thyroidectomy, goiter
recurrence, levothyroxine prophylaxis.

We recommend 100 micrograms daily thyroxine
therapy for pophylactic purposes for a relatively short
period (9 to 12 months) postoperatively to reduce the
recurrence rate.
Patients and Method
In the period from 1987 to 1992, 126 patients were
operated on for benign nodular colloidal goiter and
bilateral subtotal thyroidectomy in the General Surgery
Clinic of Karadeniz Technical University. Among those
who were prescribed prophylactic thyroxine 100 micro
grams/day for 9 to 12 months, 88 were included in the
study. The remaining 38 patients were excluded from the
study as they were not contactable. Forty-one patients
who had taken thyroxine 100 micrograms per day
postoperatively for a period of 9 to 12 monhts were
Group 1. Forty-seven patients who had not taken
thyroxine or those who had taken thyroxine for a short
period of 20 days or less, postoperatively (36 patients
none, 11 pattients 20 days or less) were Group 2. The
two groups were evaluated for postoperative
recurrences.
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No

Age

Sex TSH level

T3 level

T4 level

Time lapse

(IU/I)

(ng/dI)

mg/dI

(years)

Type of

Table 1.

Volume of

A detailed docmunet of the
recurrence cases.

recurrence recurrence (ml)

1*

20

F

1.8

152

6.5

1

nodule

45

2*

28

F

2.1

148

5.2

4

nodule

36

3*

31

F

2.4

131

8.6

8

DE

51

4

43

F

5.4

96

4.5

3

nodule

54

5

28

F

0.8

126

10.5

4

nodule

42

6

18

F

2.4

144

8.4

2

nodule

36

7

28

F

3.1

135

5.4

4

nodule

43

8

17

F

2.8

132

5.8

4

DE

55

9

19

F

1.2

110

6.8

2

DE

58

10

39

F

6.5

88

4.2

5

nodule

32

11

24

M

1.6

1.6

6.5

5

DE

74

12

32

M

3.4

112

9.4

5

nodule

46

13

23

F

3.2

113

7.4

6

nodule

57

14

30

M

2.6

140

8.8

7

nodule

37

15

24

M

3.0

104

5.8

7

nodule

43

Ave.

27

2.8

122.5

6.92

4.5

47.3

*: With thyroxine propylaxis therapy (100 micrograms/day)
DE: Diffuse enlargement
Ave.: Average
M: Male
F: Female

During the operations the inferior thyroideal artery
was not ligated rountinely and about 10 to 18 g of
thyroid tisue was left. The difference between the two
groups was not statistically significant in term of the
ages, median follow-up period, or the sexes of the
patients. In all cases, bilateral subtotal thyroidectomy was
performed. The mean follow-up period was 6.5 years
with a range of 4 to 8 years. Physical examination was
performed in all patients at least twice every year after
surgery. The diagnosis of postoperative recurrence was
confirmed by scintigraphic and ultrasonographic
examination of the thyroid. Thyroid scintigraphy was
obtained 15 minutes after an intravenous injection of 2.5
mCi of Technetium-99m pertechnetate, using a gamma
camera with a pinhole collimator (Toshiba Digital Camera
GCA-501S). Thereafter, the patient was examined
ultrasonographically using a Shimadzu SDU-500
instrument with a 3.5MHz linear, trapezoid transducer. A
sonographic pillow was used to increase the resolution.
Recurrences were defined as two consecutive thyroid
volumes greater than 28 ml (normal range 9 to 28 ml).

274

If a recurrence was diaognesd, total T3 (COAT-A count,
normal range 0.4 to 4.5IU/l) levels were determined by
radioimmunoassay method using a 1275 Vallac Mini
Gamma Goiter instrument. Time elapse between the
operation and recurrence was also recorded. The results
were compared using Fisher’s exact test.
Result
Eighty-eight patients with benign nodular colloidal
goiter were followed up evaluate postoperative
recurrences. Seventeen (19.3%) were male and 71
(80.7%) were female and their ages ranged from 17 to
62 years with a mean of 31.2 years at the time of
operation. Group 1 was composed of 8 (19.5%) men and
33 (80.5%) women with an age range of 17 to 59 years
and a mean of 29.6 years. Group 2 composed of 9
(19.1%) men and 38 (80.9%) women with an age range
of 20 to 60 years and a mean of 30.3 years.
Overall

15

(17%)

recurrences

were

seen
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postoperatively during a follow-up period ranging from 4
to 8 years (mean 6.5 years). There7.3%) recurrences
occurred in group 1 patients and 12 (25.5%) recurrences
occurred in group 2 patients. The difference between thet
two groups was statistically significant (p<0.05).
The 15 patients (4 men and 11 women) with
recurrence of nontoxic goiter were 17 to 43 years old
(average 27 years) at the time of the thyroid resection.
The mean serum T3 level in the recurrence group was
122.5 ng/dl (normal range 86-187 ng/dl) while the mean
T4 level was 6.92 mg/dl (normal range 4.5-12.5 mg/dl),
and the mean serum TSH level was 28 IU/l (normal range
0.4-4.5 IU/l) at the time of the recurrence. The time
between the operation and the recurrence was one year
in 1 case, two years in 2 cases, three years in 1 case, four
years in 4 cases, five years in 3 cases, six years in 1 case,
seven years in 2 cases and eight year in 1 case while the
average time was 4.5 years. The recurrences were in the
form of nodules in 11 patients and diffuse enlargement in
the remaining 4. The volume of the goiter ranged from
32 to 74 ml (average 47 ml) (Table 1).
Discussion
There is great debate about the optimum surgical
management of multinodular goiter. It is generally
accepted that the pathologic process or at least a
propensity towards multinodular change involves the
whole gland. Different surgeons adopt different
approaches usually involving radical surgical treatment to
prevent recurrences. Some rountinely perform bilateral
subtotal thyroidectomy even if one lobe is macroscopically
normal at the time of operation (5, 26, 27). One group
has reported good results when performing total
thyroidectomy for bilateral nodular glands (28, 29). In
comparison, our approach allows for conservative initial
surgical treatment and relatively short term prophylaxis
with thyroxine to prevent recurrences.
It has been postulated that multinodular goiter
develops as a result of TSH stimulation created by a
biochemical block in the production of thyroxine in the
thyroid gland (30, 31). This provides a clear rationale for
the use of thyroxine in multinodular goiter and as
postoperative prophylaxis. However, some researchers do
not concur with this. This is because in their series of
patients with multinodular goiter, the TSH level was not
elevated (7, 9).
The results of many reports have shown that TSH
levels are elevated after thyroid resection, probablly to
maintain a euthyroid state (32, 33). These findings

support the
patients, in
these high
prophylactic

rationale of our management policy in such
that after the operation, the reduction of
TSH levels may be accomplished with
thyroxine.

In the late 1940s, postoperative thyroxine was first
used for prevention of recurrent goiter. The favourable
results of that study were published in 1955 (34). While
some authors suggested overreplacement of thyroxine to
suppress TSH (2-3 micrograms per kilogram of body
weight daily) (6, 10-12, 15, 23-26, 35), other groups
suggested lower dose thyroxine for prophylactic purposes
(100 micrograms daily) (5, 16, 17, 22, 36). Ibis et al.
(23) reported recurrence rates of 30.7%, 46% and
81.8% for patients receiving a suppressive dose of Lthyroxine, 100 microgram/day, and for these receiving no
therapy respectively. It is evident in this study that
although L-thyroxine in doses of 100 microgram/day is
effective in preventing goiter recurrence, it gives better
result in suppressive doses. We applied 100 micrograms
thyroxine daily for prophylactic purposes (for 9 to 12
months postoperatively) to prevent hazardous effects of
the suppressive dose of thyroxine such as subclinical
hyperthyroidism in clinically euthyroid patients, and loss
of bone mineral from the spine (35, 36).
How long should suppressive or prophylactic doses of
thyroxine be used? The answer is not known exactly.
While some authors have suggested indefinite or
continuous use, (5, 6, 23-25) others propose for 6 to 18
months after the operation (10-13, 27) while still others
suggest for 3 months (11, 15). We prefer prophylactic
thyroxine doses for 9 to 12 months to minimize the
adverse effects of the long-term therapy and to ensure
patients’ compliance to the regimen, owing to its short
duration.
It is well documented that a second thyroidectomy is
a much more hazardous procedure than the first (5, 35).
Since the operative procedure does not get rid of primary
pathology, recurrence of goiter is still important after
thyroidectomy. Therefore, the prevention of recurrence
of goiter is still a problem today. In the literature,
recurrence rates vary from 5% to 30% (5, 6, 13, 14,
22, 24, 35, 37), but when data from echographic
evaluations of recurrence, particularly those performed in
endemic areas are considered, values around 80% are not
uncommon (23-25).
We found an overall recurrence rate of 17%. In group
1 the recurrence rate was 7.3% and in group 2 it was
25.5%. The difference was statistically significant
(p<0.05). TSH levels in group 1 patients were found to
be within normal limits at the time when recurrence was
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diagnosed. In group 2, we noted 12 recurrences with
slightly higher TSH levels in 2 cases while it was within
the normal limits in the other 10 cases. These results
suggest that there are other etiological factors (such as
thyroid growth immunoglobulins) to consider for
recurrences to occur in addition to high TSH levels.
We found a lower incidence of recurrence of goiter
after thyroidectomy compared with the results in the
literature especially from endemic goiter regions (5, 6,
13, 14, 22-25, 30). The length of the follow up is a
major determinant of the recurrence rate. The reported
postoperative follow-up period was much longer than in
our study. Those studies with longer follow-up periods
gave higher recurrence rates when compared to our
overall recurrence rate (23-25). The method of
diagnosing the recurrence is another important factor in
determining the recurrence rate. On physical examination,
the recurrence can only be diagnosed in 71.2% o f cases.
But by the scintigraphic and ultrasonographic
examination of the thyroid the recurrence rate rises to
80.6% and 96.4% respectively (23). We performed
scintigraphic and ultrasonographic examination only in
those patients suspected of having recurrence upon
physical examination. In addition, according to some
authors recurrence was defined as two consecutive
thyroid volumes greater than 28 ml (normal range 9 to
28 ml), or since some patients had a thyroid volume of
28 ml or greater after thyroidectomy, as two consecutive

volumes greater than the initial volume (15). Others set
the criteria to define the recurrence of nodular lesions in
the residual thyroid tissue as follows: (a) presence of a
hypoechoic or hyperechoic nodular pattern with a
maximum diameter longer than 5 mm; (c) identification
of a perinodular hypoechogenic or hyperechogenic halo;
and (c) description of an anechoic lesion with a reinforced
posterior wall (24). We used the criteria that define the
recurrences on thyroid volume basis which is less sensitive
than the others. There might be other reasons for our
lower overall recurrence rate.
Although the overall recurrence rate in our study is
lower when compared with the values in due to he abovementioned possible reasons, the difference betwen
thyroxine treated and untreated groups is still statistically
significant. We think that the choice of 100 micrograms
a day of thyroxine for a period of 9 to 12 months is
appropriate. All patients receivinig this dose are less likely
to have recurrences. Conservative surgical treatment plus
postoperative prophylactic thyroxine therapy for 9 to 12
months decreases recurrence of multinodular goiter at
least during the early follow-up period.
Correspondence author:
Adnan CALIK,
K.T.U Lojmanları 34-5 61080
Trabzon-Turkey
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